Payment overview · 2025
General Payments
$476.03
14 reported records · 6 companies
Healthcare provider profile · identity verified
Alan D. Warrington, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WILMINGTON, DE · NPI 1801981923
Verified facts
What the public records show
CMS Open Payments records show Alan D. Warrington, D.O. received $476.03 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.77 | 31.5% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $95.30 | 20.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $84.30 | 17.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $82.80 | 17.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.12 | 9.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.74 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $476.03 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $149.77 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.77 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $95.30 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $84.30 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $82.80 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
78 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 544 | 79 |
| Trazodone Hcl | Trazodone Hcl | 524 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 51 |
| Omeprazole | Omeprazole | 346 | 49 |
| Mirtazapine | Mirtazapine | 296 | 30 |
| Eliquis | Apixaban | 227 | 26 |
| Furosemide | Furosemide | 213 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 44 |
| Gabapentin | Gabapentin | 174 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 25 |
| Carvedilol | Carvedilol | 158 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 24 |
| Sertraline Hcl | Sertraline Hcl | 148 | 17 |
| Lisinopril | Lisinopril | 147 | 23 |
| Metformin Hcl | Metformin Hcl | 141 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 15 |
| Losartan Potassium | Losartan Potassium | 131 | 19 |
| Famotidine | Famotidine | 118 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 14 |
| Buspirone Hcl | Buspirone Hcl | 110 | 17 |
| Levetiracetam | Levetiracetam | 103 | suppressed |
| Simvastatin | Simvastatin | 101 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 16 |
| Cephalexin | Cephalexin | 94 | 71 |
| Montelukast Sodium | Montelukast Sodium | 93 | 13 |
| Potassium Chloride | Potassium Chloride | 85 | suppressed |
| Xarelto | Rivaroxaban | 84 | suppressed |
| Latanoprost | Latanoprost | 79 | suppressed |
| Myrbetriq | Mirabegron | 78 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 77 | 77 |
| Allopurinol | Allopurinol | 76 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 74 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | suppressed |
| Lorazepam | Lorazepam | 67 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | suppressed |
| Nystatin | Nystatin | 65 | 29 |
| Methylprednisolone | Methylprednisolone | 57 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | 12 |
| Donepezil Hcl | Donepezil Hcl | 53 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Prednisone | Prednisone | 51 | 13 |
| Monoject Insulin Safety Syrng | Syringe With Needle, Insulin | 46 | suppressed |
| Ketoconazole | Ketoconazole | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Atenolol | Atenolol | 44 | suppressed |
| Humalog | Insulin Lispro | 44 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 37 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Lacosamide | Lacosamide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 30 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 35 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 13 |
| Budesonide | Budesonide | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 26 |
| Veltassa | Patiromer Calcium Sorbitex | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 18 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 23 | 11 |
| Jardiance | Empagliflozin | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Topiramate | Topiramate | 22 | suppressed |
| Victoza 3-Pak | Liraglutide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 16 |
| Meloxicam | Meloxicam | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nystop | Nystatin | 19 | 11 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 16 |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 11 |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 17 | 16 |
| Vancomycin Hcl | Vancomycin Hcl | 17 | suppressed |
| Admelog Solostar | Insulin Lispro | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Acyclovir | Acyclovir | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Voriconazole | Voriconazole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.03 · 14 records | ABBVIE INC. | Leqembi, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, Veozah, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error